1) Majority of Lovenox ANDA work was done much before wheeler's arrival in Momenta, MIT, . ANDA I believe was filed in 03(or 05?)
2) Much of the leg work for Copaxone ANDA was done before wheeler's arrival, although they have continued to work on Copaxone ANDA during the last few years. ANDA was filed in 2007
3) Now, their burn rate is 60-80m/year(not sure what the run rate was from 2006-2010). This is big money. (To know what could be done by that amount of capital in 2 years, you only need to turn to Amarin. Of-course it's all about risk/risk mitigation. Amarin in it's previous avatar was a failure. But ton of information/studies on importance of EPA in CV, Epadel usage in Japan, $1billion Lovaza sales in US just for one of the indications, made the management/scientific team at Amarin make the right extremely low risk investment. That investment is now valued by the market approx $2 billion) I would like to see that spend deliver mid term value 2-3 years. I would like more transparency of that spend esp on FOB front. What value are they building for shareholders on the FOB side? Currently it is a blackbox, other than "wheeler platform talk"...no means to value.
Now they claim to have built FOB platform and wheeler's litmus test is in forging a profitable partnership with say a major pharma like Pfizer or Amgen, that can not only bring "commercial"(manufacturing and marketing) capabilities, but (I am hoping) would bring $ to the table for the next few years, so MNTA can scale up it's characterization capabilities . The wheeler talk on this subject so far is good..He makes it sound like he wants a perfect strategic partnership, he probably wants a fair partnership stake for MNTA, he also says using bank balance for building manufacturing capabilities is not good use of money.
I have asked myself why wouldn't these guys use the huge cash to scale up on characterization capabilities(so they go after all major biologics). But wheeler said he is operating business for worst case scenario (TL launch and No MC until 2014 patent)..implying he doesn't want to dilute again.
4)They also have done some research work on 2 products(1 clinical and 1 still pre-clinical). But nothing significant as far as I am concerned. Still a long value from commercializing...and clinical drug is still in limbo for an extended period. The other one IND needs to be filed
So you get the gist of what i am looking for from wheeler.
Market Data 
Markets 
AI
